Literature DB >> 32311117

Fluorescence and Multiphoton Imaging for Tissue Characterization of a Model of Postmenopausal Ovarian Cancer.

Travis W Sawyer1, Jennifer W Koevary2, Caitlin C Howard2, Olivia J Austin2, Photini F S Rice2, Gabrielle V Hutchens2, Setsuko K Chambers3, Denise C Connolly4, Jennifer K Barton1,2.   

Abstract

BACKGROUND AND OBJECTIVES: To determine the efficacy of targeted fluorescent biomarkers and multiphoton imaging to characterize early changes in ovarian tissue with the onset of cancer. STUDY DESIGN/
MATERIALS AND METHODS: A transgenic TgMISIIR-TAg mouse was used as an animal model for ovarian cancer. Mice were injected with fluorescent dyes to bind to the folate receptor α, matrix metalloproteinases, and integrins. Half of the mice were treated with 4-vinylcyclohexene diepoxide (VCD) to simulate menopause. Widefield fluorescence imaging (WFI) and multiphoton imaging of the ovaries and oviducts were conducted at 4 and 8 weeks of age. The fluorescence signal magnitude was quantified, and texture features were derived from multiphoton imaging. Linear discriminant analysis was then used to classify mouse groups.
RESULTS: Imaging features from both fluorescence imaging and multiphoton imaging show significant changes (P < 0.01) with age, VCD treatment, and genotype. The classification model is able to classify different groups to accuracies of 75.53%, 69.53%, and 86.76%, for age, VCD treatment, and genotype, respectively. Building a classification model using features from multiple modalities shows marked improvement over individual modalities.
CONCLUSIONS: This study demonstrates that using WFI with targeted biomarkers, and multiphoton imaging with endogenous contrast shows promise for detecting early changes in ovarian tissue with the onset of cancer. The results indicate that multimodal imaging can provide higher sensitivity for classifying tissue types than using single modalities alone. Lasers Surg. Med.
© 2020 Wiley Periodicals, Inc. © 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  fluorescence imaging; multiphoton imaging; ovarian cancer

Year:  2020        PMID: 32311117      PMCID: PMC7572562          DOI: 10.1002/lsm.23251

Source DB:  PubMed          Journal:  Lasers Surg Med        ISSN: 0196-8092            Impact factor:   4.025


  48 in total

1.  Interpreting second-harmonic generation images of collagen I fibrils.

Authors:  Rebecca M Williams; Warren R Zipfel; Watt W Webb
Journal:  Biophys J       Date:  2004-11-08       Impact factor: 4.033

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.

Authors:  Nuzhat Ahmed; Clyde Riley; Greg Rice; Michael Quinn
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

4.  Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.

Authors:  Camille Maringe; Sarah Walters; John Butler; Michel P Coleman; Neville Hacker; Louise Hanna; Berit J Mosgaard; Andy Nordin; Barry Rosen; Gerda Engholm; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Colleen E McGahan; David Meechan; Richard Middleton; Elizabeth Tracey; Donna Turner; Michael A Richards; Bernard Rachet
Journal:  Gynecol Oncol       Date:  2012-06-27       Impact factor: 5.482

5.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Authors:  Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

Review 6.  Ovarian cancer: involvement of the matrix metalloproteinases.

Authors:  Linah Al-Alem; Thomas E Curry
Journal:  Reproduction       Date:  2015-04-27       Impact factor: 3.906

7.  Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Authors:  Harvey Hensley; Bridget A Quinn; Ronald L Wolf; Samuel L Litwin; Seiji Mabuchi; Stephen J Williams; Christine Williams; Thomas C Hamilton; Denise C Connolly
Journal:  Cancer Biol Ther       Date:  2007-08-03       Impact factor: 4.742

8.  Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.

Authors:  Xiaoxia Hu; Danrong Li; Wei Zhang; Jie Zhou; Bujian Tang; Li Li
Journal:  Arch Gynecol Obstet       Date:  2012-07-26       Impact factor: 2.344

9.  Loss of ovarian function in the VCD mouse-model of menopause leads to insulin resistance and a rapid progression into the metabolic syndrome.

Authors:  Melissa J Romero-Aleshire; Maggie K Diamond-Stanic; Alyssa H Hasty; Patricia B Hoyer; Heddwen L Brooks
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-05-13       Impact factor: 3.619

Review 10.  Development of an animal model for ovotoxicity using 4-vinylcyclohexene: a case study.

Authors:  Patricia B Hoyer; I Glenn Sipes
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2007-04
View more
  1 in total

1.  Ovarian cancer detection using optical coherence tomography and convolutional neural networks.

Authors:  David Schwartz; Travis W Sawyer; Noah Thurston; Jennifer Barton; Gregory Ditzler
Journal:  Neural Comput Appl       Date:  2022-01-24       Impact factor: 5.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.